Leerink Partners analyst Joseph Schwartz maintained a Buy rating on Aurinia Pharmaceuticals (NASDAQ:AUPH) on Tuesday, setting a price target of $28, which is approximately 33.91% above the present share price of $20.91.
Schwartz expects Aurinia Pharmaceuticals to post earnings per share (EPS) of -$0.37 for the third quarter of 2021.
The current consensus among 5 TipRanks analysts is for a Strong Buy rating of shares in Aurinia Pharmaceuticals, with an average price target of $28.8.
The analysts price targets range from a high of $35 to a low of $23.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $6.62 million and a net profit of -$47.13 million. The company's market cap is $2.68 billion.
According to TipRanks.com, Leerink Partners analyst Joseph Schwartz is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 10.6% and a 47.94% success rate.
Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases particularly lupus nephritis. The company was founded by Robert Foster, Richard Glickman and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.